Love Maharashtra? Then you wil love Marathikatta!
Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                    Movies   Aviation   Pharma   About Us   Feedback   Links
ZYDUS BUYS JAPAN PHARMA CO.
 

Zydus Cadila acquires Japanese firm


BY OUR PHARMA CORRESPONDENT

20 April,2007:

In what could be termed as one of the big Indian forays into the world’s second largest pharma market, Zydus Cadila acquired 100 per cent stake in Nippon Universal Pharmaceutical Ltd, Tokyo.

Nippon provides an opportunity for the group to establish itself in Japan's rapidly evolving generics space. The Japanese generics market valued at $3 bn has a tremendous growth potential as it currently stands at just 5 per cent of the total pharma market in Japan in value terms and 17 per cent by volume. The acquisition will provide critical access to a ready manufacturing and marketing base as well as a strong distribution reach. Nippon reaches out countrywide to more than 4000 hospitals and clinics. This is expected to provide a fillip to the group's operations in a market that is highly complex and dominated by local pharma companies.

Ahmedabad based Zydus which had set up Zydus Pharma Inc in 2006 to spearhead its foray in the generics market of Japan will now be able to jumpstart its operations. Zydus will be looking to leverage Nippon's strong relationship with key wholesalers, which spans over three decades.

The group has identified a new product development programme that will feed at least 5 to 6 products each year to their portfolio and build a basket of 40-50 products over the next 3 to 4 years. Moreover Zydus will acquire new marketing authorisations (MA) from the market to cut short on development time and would also explore in-licensing agreements with other generic companies. With a sizeable number of products in its portfolio, the group will also be looking to expand the field force to cover new areas and customers in the medium term, the company said in a press statement.

In this highly regulated market with high expectations in terms of quality and consistency of supplies, companies looking to consolidate their presence have found the acquisition route the most ideal one.

This marks Zydus Cadila's second overseas acquisition, the first being Alpharma France in 2003. With a turnover of over Rs 1800 crore, Zydus Cadila is a global healthcare provider and amongst the leading healthcare groups in India. Starting with the acquisition of Recon Healthcare in 2000, Zydus Cadila went on to acquire German Remedies Ltd., in 2001 and Banyan Chemicals in 2002. Most recently the group made a foray in the 1500 crore Derma market in India with the acquisition of the Mumbai-based, Liva Healthcare.

 

BY OUR PHARMA CORRESPONDENT

   

 

 

Auto news for auto freaks! iDrive.in
DWS community! / Cricket blog

 

Latest Stories in Pharma

 

Protect your children from passive smoking

The environmental and health costs of plastic

Reiki - Key to empowerment

Zydus Cadila acquires Japanese firm

Indian HIV vaccine lead promising

Hormone pill to stop menstruation on way

Most neuro pains go undiagnosed

Rising health care costs hit women harder than men

Shun beef, pregnant women told

Hard drinking more harmful than Ecstacy drug

 

Latest Stories in Pharma

Pharma stories archived on 7 Jan 2007

Pharma stories archived on 14 Sep, 2005

 

Home Politics Religion Media Biz Society Tech Travel Books Intl. Autos Automobiles
                        Aviation   Pharma   About Us   Feedback   Links

Latest updates    Contact Us - Feedback    About Us